Precision Medicine Supply Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Clinical, Commercial), By Service (Transportation, Warehousing, Sourcing & Procurement, Others), By Product (Cell & Gene Therapies (CGT), Monoclonal Antibodies, Nucleic Acid Therapies, Vaccines, Others), By End User (Pharmaceutical and Biopharmaceutical Companies, Clinical Research Organizations, Others), By Region and Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 8.39 Billion
CAGR (2026-2031)	12.13%
Fastest Growing Segment	Nucleic Acid Therapies
Largest Market	North America
Market Size (2031)	USD 16.68 Billion

Market Overview

The Global Precision Medicine Supply Chain Logistics Market is projected to grow from USD 8.39 Billion in 2025 to USD 16.68 Billion by 2031 at a 12.13% CAGR. Precision medicine supply chain logistics encompasses the specialized management, storage, and transportation of highly individualized and temperature-sensitive medical products, such as cell and gene therapies and companion diagnostics, from their point of origin to the patient. This intricate system ensures the integrity, traceability, and timely delivery essential for personalized treatments. Growth in this market is primarily driven by the escalating number of approved precision medicine therapies demanding strict cold chain adherence and expedited transport, along with expanding global investments in advanced biopharmaceutical research and development.

According to the International Air Transport Association (IATA), in 2025, global air cargo demand increased by 3.4% year on year, reflecting the critical role air freight plays in the rapid movement of high-value pharmaceutical products. A significant impediment to market expansion remains the substantial cost and complexity associated with establishing and maintaining ultra-low temperature logistics infrastructure and ensuring meticulous end-to-end traceability across varied international regulatory frameworks.

Key Market Drivers

Cell and Gene Therapy Expansion and Cold-Chain Demands
The expansion of cell and gene therapy development significantly drives the Global Precision Medicine Supply Chain Logistics Market, necessitating specialized capabilities for ultra-cold storage, cryogenic transport, and precise handling. These therapies, often autologous or allogeneic, have extremely short shelf lives and require strict temperature excursions, demanding robust cold chain infrastructure and real-time monitoring solutions. According to the American Society of Gene & Cell Therapy, in January 2025, over 4,000 gene, cell, and RNA-based treatments were in research and development globally, underscoring the increasing volume and complexity of products requiring tailored logistical pathways from manufacturing to patient administration. This growing pipeline intensifies the need for expert logistics providers capable of managing complex chain of custody and identity.

Clinical Trial Growth and Precision Medicine Logistics
Concurrently, the growing number of precision medicine clinical trials fuels demand for specialized logistics, particularly for investigational products and companion diagnostics. The global nature of these trials, coupled with stringent regulatory requirements, mandates end-to-end traceability and meticulous temperature control for sensitive biological samples and therapeutic agents. According to BioSpace, in December 2025, phase I–III clinical trial starts increased by 20% year over year by mid-2025, highlighting the accelerated pace of research that directly translates into increased logistical demands for trial initiation and execution. The intricate coordination required for global clinical supply distribution contributes to the overall market growth for specialized precision medicine logistics, with companies actively investing in capabilities to support this segment. According to DHL Group, in March 2025, its Life Sciences and healthcare division generated over EUR 5 billion (USD 5.41 billion) in revenue in 2024, demonstrating substantial financial activity in supporting complex biopharmaceutical supply chains.

Download Free Sample Report

Key Market Challenges

A significant impediment to the growth of the global precision medicine supply chain logistics market stems from the substantial cost and inherent complexity associated with establishing and maintaining ultra-low temperature logistics infrastructure and ensuring meticulous end-to-end traceability across diverse international regulatory frameworks. Developing and deploying the specialized facilities required for cell and gene therapies demands considerable capital outlay and ongoing operational expenses. According to the International Society for Pharmaceutical Engineering (ISPE), in February 2026, setting up a compliant cold storage facility in the U.S. can cost upwards of $2 million, excluding ongoing maintenance and energy expenditures. This considerable financial barrier limits investment capacity for many market participants, particularly smaller and medium-sized enterprises, thereby constraining overall market expansion.

Beyond the financial implications, the operational complexity involved in managing these highly sensitive products further restricts market development. Precision medicine therapies necessitate strict adherence to ultra-low temperature ranges, often requiring specialized cryogenic storage and transport, alongside a rigorous system for product traceability. Navigating varied international regulatory standards for temperature control and documentation adds layers of complexity, increasing the potential for non-compliance and product integrity issues. This intricate operational landscape necessitates specialized expertise and robust quality management systems, posing a formidable challenge for scalability and consistent service delivery across global networks.

Key Market Trends

The Global Precision Medicine Supply Chain Logistics Market is experiencing a notable shift towards direct-to-patient and decentralized logistics models. This trend is driven by the individualized nature of precision medicines, often requiring direct delivery to patient homes or local care settings. Such models enhance patient access and convenience for time-sensitive therapies. Specialized final-mile delivery services are increasingly critical. According to DHL Group, in September 2025, its acquisition of SDS Rx, a provider of specialized healthcare transportation, underscored this importance, with specialty pharmacy already accounting for approximately 50% of total prescription drug spending in the U.S.. This necessitates robust infrastructure for direct delivery, including real-time tracking and temperature-controlled transport.

Another significant trend reshaping the precision medicine logistics landscape is the increasing number of strategic partnerships and collaborations among logistics providers and biopharmaceutical companies. These alliances leverage specialized expertise, expand geographical reach, and mitigate the substantial costs and complexities inherent in precision medicine supply chains. Collaborations often focus on developing integrated, end-to-end solutions for ultra-cold storage, cryogenic transport, and intricate regulatory compliance. A clear illustration is UPS Healthcare's ambitious growth strategy. According to Daniel Gagnon, UPS Healthcare's Vice President of Global Strategy & M&A, in February 2026, UPS aims to achieve $20 billion in annual healthcare revenue by 2026, a target largely supported by strategic acquisitions and new ventures. Such partnerships enable the quicker scaling of specialized services and the integration of advanced technologies.

Segmental Insights

Nucleic Acid Therapies represent the fastest-growing segment within the Global Precision Medicine Supply Chain Logistics Market. This rapid expansion is primarily driven by breakthroughs in messenger RNA, RNA interference, and CRISPR technologies, enabling precise gene regulation for a wide spectrum of diseases. The increasing global prevalence of chronic and genetic disorders further necessitates personalized treatment options that these therapies offer. Additionally, regulatory bodies like the Food and Drug Administration, through its Division of Translational and Precision Medicine, actively promote the development and review of genetically targeted therapies, thereby increasing the demand for specialized and compliant logistics solutions to support these innovative medical advancements.

Regional Insights

North America holds a dominant position in the Global Precision Medicine Supply Chain Logistics Market. This leadership is largely due to the region's advanced healthcare infrastructure, well-established cold chain networks, and a concentrated presence of precision medicine developers. The robust regulatory environment, including comprehensive guidelines from the U.S. Food and Drug Administration, ensures strict adherence to compliance and safety standards for handling specialized biologics. Additionally, significant investments in research and development by pharmaceutical and biotechnology companies, alongside a strong emphasis on personalized medicine, further solidify North America's leading role in the market.

Recent Developments

• In April 2026, Marken UPS Healthcare Precision Logistics enhanced its Laboratory Advantage service line by leveraging advanced digital technologies such as Artificial Intelligence (AI), Radio Frequency Identification (RFID), and the Internet of Things (IoT). These technological integrations are improving visibility, real-time tracking, and informed decision-making within clinical trial supply chains. This development is crucial for the global precision medicine supply chain logistics market, as it enables reliable data collection and maintains strict sample integrity for the complex and sensitive biological materials inherent in precision medicine clinical research and development.
• In December 2025, a strategic collaboration agreement was formed between SCTbio and Fortrea, aiming to simplify the development process and accelerate timelines for advanced therapies. This partnership is vital for the global precision medicine supply chain logistics market as it focuses on rapidly bringing complex, personalized treatments to patients. By integrating efforts to streamline development, the collaboration intends to optimize the logistical pathways and reduce the complexities often associated with the highly sensitive and time-critical nature of advanced therapeutic products, ensuring more efficient patient access.
• In October 2025, Orsini, a company specializing in rare disease pharmacy solutions, introduced its integrated specialty pharmacy and third-party logistics (3PL) solution. This new offering, supported by the company's facility in Columbus, Ohio, addresses the unique and complex supply chain requirements for rare disease treatments. The launch streamlines the distribution process for highly specialized medications, which are often a core component of precision medicine, by combining pharmacy services with dedicated logistics expertise, thereby enhancing the operational efficiency within the global precision medicine supply chain.
• In January 2025, Cryoport, Inc. launched its new Cryoport Express Cryogenic HV3 Shipping System, representing a significant advancement in the global precision medicine supply chain logistics market. This system provides a comprehensive portfolio for the secure and efficient transportation of life-saving biologics and other highly temperature-sensitive therapies. The innovative HV3 system is designed to maintain precise cryogenic temperatures, ensuring product integrity for complex personalized medicines from manufacturing sites to patients worldwide. This directly supports the increasing demand for ultra-cold chain capabilities crucial for advanced therapeutic development and delivery.

Key Market Players

• Almac Group Limited
• Catalent, Inc.
• Parexel International Corporation
• IQVIA Holdings Inc.
• Thermo Fisher Scientific Inc.
• DHL International GmbH
• Federal Express Corporation
• UPS Healthcare
• GXO Logistics, Inc.
• Marken Limited

By Type	By Service	By Product	By End User	By Region
Clinical Commercial	Transportation Warehousing Sourcing & Procurement Others	Cell & Gene Therapies (CGT) Monoclonal Antibodies Nucleic Acid Therapies Vaccines Others	Pharmaceutical and Biopharmaceutical Companies Clinical Research Organizations Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Precision Medicine Supply Chain Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Precision Medicine Supply Chain Logistics Market, By Type:

• Clinical
• Commercial

• Precision Medicine Supply Chain Logistics Market, By Service:

• Transportation
• Warehousing
• Sourcing & Procurement
• Others

• Precision Medicine Supply Chain Logistics Market, By Product:

• Cell & Gene Therapies (CGT)
• Monoclonal Antibodies
• Nucleic Acid Therapies
• Vaccines
• Others

• Precision Medicine Supply Chain Logistics Market, By End User:

• Pharmaceutical and Biopharmaceutical Companies
• Clinical Research Organizations
• Others

• Precision Medicine Supply Chain Logistics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE